Piramal R&D Spinoff Gets Name, Seeks Foreign Partner
This article was originally published in PharmAsia News
Executive Summary
Piramal Healthcare's recently spun-off research and development arm has been named Piramal Life Sciences as it seeks a foreign partner. The new partner, which would have a 10 percent equity in the new company, is expected to be a multinational drug maker with a strong emphasis on drug discovery. The R&D firm has 14 compounds in its research pipeline, four of them undergoing clinical trials, and it already has discovery and development agreements with Lilly, Merck and other major drug research companies. (Click here for more